Fasenra treatment should be initiated by a physician experienced in the diagnosis and treatment of severe asthma.
Posology: The recommended dose is 30 mg of FASENRA by subcutaneous injection every 4 weeks for the first 3 doses, and then every 8 weeks thereafter.
Fasenra is intended for long-term treatment. A decision to continue the therapy should be made at least annually based on disease severity, level of exacerbation control and blood eosinophil counts.
Paediatric population: The safety and efficacy of FASENRA in children aged 6 to 18 years have not been established.
No data are available for children aged 6 to 11 years old. Currently available data in children 12 to less than 18 years old are described in Adverse Reactions, Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions but no recommendation on a posology can be made.
Elderly patients: No dose adjustment is required for elderly patients (see Pharmacology: Pharmacokinetics under Actions).
Renal and hepatic impairment: No dose adjustment is required for patients with renal or hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).
Method of administration: FASENRA is administered as a subcutaneous injection. In line with clinical practice, monitoring of patients after administration of biologic agents is recommended (see Hypersensitivity reactions under Precautions).
Administer FASENRA into the upper arm, thigh, or abdomen. If somebody else administers the injection, the upper arm can also be used. Do not administer into areas where the skin is tender, bruised, erythematous, or hardened.
A patient may self-inject FASENRA or the patient's caregiver may administer FASENRA if their healthcare professional determines it is appropriate. However, the healthcare professional should ensure appropriate initiation and follow-up of patients. Proper training in subcutaneous injection technique using the prefilled syringe should be provided according to the Instructions for use under Patient Counselling Information.